ARTICLE | Clinical News
CHMP backs Luxturna, Lilly's migraine mAb, antibiotic Vabomere
September 28, 2018 5:25 PM UTC
EMA's CHMP on Sept. 21 recommended several therapies for approval, including gene therapy Luxturna voretigene neparvovec, migraine mAb Emgality galcanezumab and antibiotic Vabomere meropenem/vaborbactam.
CHMP also confirmed its negative opinion for Exondys eteplirsen from Sarepta Therapeutics (NASDAQ:SRPT) for Duchenne muscular dystrophy...
BCIQ Company Profiles